Ludwig Enterprises, Inc. is a technology and health related company that is developing products that use mRNA-based genetic markers with the potential to measure the presence of inflammation, and, as a result, inflammatory-driven diseases and monitor patient response to treatment. Its proprietary mRNA genomic technology has the potential of screening for genetic biomarkers for inflammatory-driven diseases, including, but not limited to, heart disease, diabetes, preeclampsia, cancer and long COVID. The Company employs a non-invasive cheek swab test to collect mRNA samples. Its initial product candidate is the Revealia Breast test, a non-invasive cheek swab assay designed to detect molecular signatures in mRNA expression associated with the presence of breast cancer. Its technology platform integrates three key components: non-invasive sample collection, genomic analysis, and machine learning-based interpretation.